Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 15;10(7):e005063. doi: 10.1136/jitc-2022-005063

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

CD40 ×HER2 bsAb overcame trastuzumab resistance in the xenograft model. (A) Experimental scheme of CD40 ×HER2 bsAb treatment in NCI-N87-tumor-bearing Balb/c nude mice. The different treatment groups included: (1) the stable control NCI-N87 cells with the trastuzumab treatment (NCI-N87-vector+Tra group), (2) the stable CCL2 overexpressing NCI-N87 cells with the trastuzumab treatment (NCI-N87-CCL2+Tra group), (3) the stable CCL2 overexpressing NCI-N87 cells with the trastuzumab and agonistic anti-CD40 mAb treatment (NCI-N87-CCL2+anti-CD40+Tra group), (4) the stable CCL2 overexpressing NCI-N87 cells with CD40 ×HER2 bsAb treatment (NCI-N87-CCL2+CD40×HER2 bsAb group). (B–D) Tumor growth curves (B), tumor weight (C) and tumor volume images (D) of each group were shown. (E–G) IHC staining for CCL2 and caspase three was presented (E), and the IHC scores for CCL2 (F) and caspase 3 (G) were statistically analyzed. (H) The gating strategy to identify CD45⁺ CD11b⁺ F4/80⁺ CD206^+/- TAMs in mouse tumor tissues. (I, J) The infiltrating CD45⁺ CD11b⁺ F4/80⁺ CD206^- (I) or CD45⁺ CD11b⁺ F4/80⁺ CD206⁺ (J) TAMs percentages in the whole cell counts detected by flow cytometry were statistically analyzed. (K–N) IHC staining for F4/80, CD86, and CD206 was presented to show the infiltrating TAMs in mouse tumors (K). IHC scores for F4/80 (L), CD86(M) and CD206 (N) were statistically analyzed. n=5 per group. tra, trastuzumab treatment. Scale bar, ×40, 500 µm; ×200, 100 µm. *P<0.05, **p<0.01, ***p<0.001. bsAb, bispecific antibody; IHC, immunohistochemistry; ns, not significant.

HHS Vulnerability Disclosure